Mukul Minocha

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip et al. · New England Journal of Medicine · 2023 · 390 citations

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai et al. · Journal of Clinical Oncology · 2023 · 250 citations · Full text

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Brian G. Feagan, Julián Panés, Marc Ferrante et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 156 citations · Full text

Autoimmune Disease, Open-label Extension Study, Immunology +5

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors

Mukul Minocha, Varun Khurana, Bin Qin et al. · International Journal of Pharmaceutics · 2012 · 80 citations · Full text

Neuro-oncology, Co-administration Strategy, Medicine +9

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib

Mukul Minocha, Varun Khurana, Bin Qin et al. · International Journal of Pharmaceutics · 2012 · 64 citations · Full text

Enhanced Brain Accumulation, Medicine, Neuropharmacology +5